Avadel Pharmaceuticals to Present at Jefferies Virtual Healthcare Conference

DUBLIN, Ireland, June 01, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc AVDL a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness and cataplexy in patients with narcolepsy, today announced that members of the Avadel management team will participate in a virtual fireside chat at the Jefferies Healthcare Conference at 10:00 a.m. ET on Thursday, June 4, 2020.

A live webcast of the event will be available at the "Investors" section of the Company's website at www.avadel.com. A replay of the webcast will be available on Avadel's website for 90 days following the presentation.

Date: Thursday, June 4, 2020

Time: 10:00 a.m. ET

Presenters:

• Greg Divis, Chief Executive Officer
• Jordan Dubow, M.D., Chief Medical Officer
• Thomas McHugh, Chief Financial Officer   

About Avadel Pharmaceuticals plc:

Avadel Pharmaceuticals plc AVDL is an emerging biopharmaceutical company. The Company's primary focus is the development and potential FDA approval of FT218, which has completed a Phase 3 clinical trial for the treatment of narcolepsy patients suffering from excessive daytime sleepiness (EDS) and cataplexy. In addition, Avadel develops and markets a portfolio of sterile injectable drugs used in the hospital setting. For more information, please visit www.avadel.com.

Contacts:

Investor Contacts

Tom McHugh

Chief Financial Officer

Phone: (636) 449-1843

Email: tmchugh@avadel.com

             

Tim McCarthy

LifeSci Advisors, LLC

Phone: (212) 915.2564

Email: tim@lifesciadvisors.com

Media Contact

Patrick Bursey

LifeSci Communications, LLC

Phone: (646) 970-4688

Email: pbursey@lifescicomms.com